Sagamihara, Japan

Hidetoshi Morita

This inventor holds 14 USPTO granted patents and 2 published patent applications and 4 EPO patents, primarily in Immunotherapy Research. Top assignees: Azabu Veterinary Medicine Educational Institution, The University of Tokyo, Riken Corporation. Active years: 2014-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hidetoshi Morita. Retrieved from https://idiyas.com/inventor/hidetoshi-morita

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 14 

% Patents Active = 92.9

 

Average Co-Inventor Count = 4.7

ph-index = 8

Forward Citations = 232(Granted Patents)


Location History:

  • Kanagawa, JP (2014 - 2019)
  • Sagamihara, JP (2017 - 2023)

Company Filing History:


Years Active: 2014-2025

Loading Chart...
Loading Chart...
Areas of Expertise:
Regulatory T Cells
Th17 Cells
Human-Derived Bacteria
Immunotherapy
Dioxin Elimination
Cell Proliferation
Compositions
Methods
14 patents (USPTO):Explore Patents

Title: Hidetoshi Morita: Innovator in Immunology

Introduction

Hidetoshi Morita is a prominent inventor based in Sagamihara, Japan. He has made significant contributions to the field of immunology, particularly through his innovative research and development of pharmaceutical compositions. With a total of 14 patents, Morita's work has the potential to impact various medical applications.

Latest Patents

Morita's latest patents focus on groundbreaking compositions and methods for the induction of Th17 cells. His research has demonstrated that strains of human-derived bacteria, obtained from complex fecal samples, can induce the accumulation of Th17 cells in the intestine and enhance immune functions. These pharmaceutical compositions containing these bacteria are poised to be used as anti-infectives and as adjuvants in mucosal vaccines. Additionally, he has developed methods for treating graft-versus-host disease by administering pharmaceutical compositions containing bacterial strains from the Clostridia class. These human-derived bacteria have shown promise in inducing the accumulation of regulatory T cells (Treg cells) in the colon, which can help mitigate pathological immune responses.

Career Highlights

Morita has worked with esteemed institutions such as the University of Tokyo and the Azabu Veterinary Medicine Educational Institution. His research has not only advanced scientific understanding but also paved the way for new therapeutic strategies in immunology.

Collaborations

Some of Morita's notable coworkers include Kenya Honda and Koji Atarashi. Their collaborative efforts have contributed to the success of his research initiatives.

Conclusion

Hidetoshi Morita's innovative work in immunology, particularly through his latest patents, showcases his dedication to advancing medical science. His contributions have the potential to lead to significant improvements in the treatment of immune-mediated diseases.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…